ODIN: Record year with improved results, strong equity, and focus on veterinary market entry in 2026
· Issued by Odinwell AB
2025 marked a record year with technological advances, clinical validation, and a strengthened financial position. Revenue declined slightly, but losses narrowed and equity improved, with commercialization in veterinary medicine prioritized for 2026 and sales expected in 2027.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
